Recent platform briefings dated 2026-09-11 and 2026-09-19 noted no material verified news events for UnitedHealth Group Inc. beyond what is captured in regulatory filings [Brief - 2026-09-19] [Brief - 2026-09-11]. The reports confirmed that trailing twelve-month revenue remained a central data point for the period, with no additional narrative details available from those briefings beyond what appears in the underlying filings and ownership disclosures referenced below.
As of the quarter ended 2026-06-30, UnitedHealth Group recorded trailing twelve-month revenue of $450.1 billion, representing year-over-year growth of 0.37%. Net income on a TTM basis was $14.9 billion, producing a net margin of 3.30% and an operating margin of 4.82%. EPS grew 61.50% year-over-year. The company held $28.6 billion in cash against total debt of $73.3 billion. Market capitalisation stood at approximately $340.8 billion, with a P/E ratio of 24.17 [SEC 10-Q - UNH - 2026-06-30].
Insider activity in September 2026 comprised 16 transactions with a mixed net direction and a net value of zero, indicating no dominant disposition or acquisition trend among insiders during the period [SEC Form 4 - UNH - 2026-09]. On the institutional side, Citadel reduced its position by 27% and Millennium reduced its position by 14%, while Tiger Global trimmed its holding by 15%. AQR Capital added 80% to its existing position, and Bridgewater opened a new position in UNH [SEC 13F - Citadel - Q2 2026] [SEC 13F - Millennium - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Tiger Global - Q2 2026] [SEC 13F - Bridgewater - Q2 2026].
The prevailing macroeconomic environment as of the report date shows the 10-year US Treasury yield at 5.18% and the 2-year yield at 4.87%, producing a normal yield curve shape [FRED DGS10] [FRED DGS2]. This report was generated in response to material institutional position changes identified across multiple 13F disclosures for the most recently reported quarter.